
CVS Health Corporation (CVS)
$
76.75
+1.75 (2.28%)
Key metrics
Financial statements
Free cash flow per share
4.9590
Market cap
102 Billion
Price to sales ratio
0.2589
Debt to equity
1.1210
Current ratio
0.8319
Income quality
5.6124
Average inventory
18.2 Billion
ROE
0.0062
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
CVS Health Corporation provides a comprehensive range of health services across the United States, demonstrating its commitment to meet the diverse needs of its clientele. The company’s Health Care Benefits segment offers a variety of health insurance products, including traditional, voluntary, and consumer-directed options, aimed at employer groups, individuals, college students, part-time workers, and various other organizations such as health plans and governmental units. With a net income ratio of 0.01 reflecting its profitability margin, CVS Health showcases its financial strength through an operating income of $8,516,000,000.00 indicative of its core operational earnings. The company earned an interest income of $0.00 showcasing its financial investments and ability to generate revenue outside its primary services. Additionally, the gross profit stands at $51,401,000,000.00 highlighting the effectiveness of its core operations. In its Pharmacy Services segment, CVS Health offers pharmacy benefit management solutions, including plan design, formulary management, and specialty pharmacy services, catering to a wide range of clients from employers to individuals. This segment plays a crucial role in managing medication needs and delivering tailored health care solutions. As of December 31, 2021, CVS Health operated approximately 9,900 retail locations and 1,200 MinuteClinic facilities, further affirming its extensive presence in the health care market. Within the financial landscape, CVS Health's stock is identified with the symbol 'CVS', attracting a variety of investors. The stock is affordable at $74.92 suitable for budget-conscious investors, while its high average trading volume of 7,535,390.00 indicates strong liquidity. With a large market capitalization of $97,428,943,224.00 the company stands as a dominant player in the health services industry, contributing significantly to the overall market landscape. As it belongs to the Healthcare sector, CVS Health is instrumental in driving innovation and growth, shaping the future of health care delivery and access. This strategic positioning not only enhances its market influence but also ensures it remains a pivotal force within the evolving health care industry.
Investing in CVS Health Corporation (CVS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict CVS Health Corporation stock to fluctuate between $43.56 (low) and $85.15 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-12-04, CVS Health Corporation's market cap is $97,428,943,224, based on 1,269,432,485 outstanding shares.
Compared to Eli Lilly & Co., CVS Health Corporation has a Lower Market-Cap, indicating a difference in performance.
CVS Health Corporation pays dividends. The current dividend yield is 3.28%, with a payout of $0.67 per share.
To buy CVS Health Corporation (CVS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CVS. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
CVS Health Corporation's last stock split was 2:1 on 2005-06-07.
Revenue: $372,809,000,000 | EPS: $3.66 | Growth: -43.61%.
Visit https://www.cvshealth.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $111.25 (2022-02-08) | All-time low: $43.56 (2024-12-23).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News

fool.com
HCA Healthcare is posting excellent results while continuing to implement a strategy that should drive a strong performance over the next 10 years. CVS Health is gradually implementing changes that will help it put the weak bottom-line performances of the past few years behind it.

zacks.com
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock?

zacks.com
CVS posts a sharper MBR as PDR impacts ease and government business strengthens while maintaining a cautious full-year outlook.

invezz.com
US stocks have been in a sharp uptrend over the past seven months, with the benchmark S&P 500 index currently up more than 35% versus its year-to-date low in April. Still, a handful of outperformers are trading at relatively low forward valuations heading into 2026.

zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com
CVS posts record Q3 revenues and a sharp EPS jump, lifting its 2025 outlook, while momentum builds across Aetna, Health Services and Pharmacy.

fool.com
CVS Health is successfully navigating industrywide and company-specific headwinds while maintaining a solid dividend program. Johnson & Johnson's rock-solid balance sheet and ability to develop brand-new products make its 62-year dividend growth streak safe.

reuters.com
Eli Lilly is dropping CVS Health's drug benefit plan for its employees after CVS stopped covering its weight-loss drug in favor of a rival medication from Novo Nordisk , Bloomberg News reported on Tuesday, citing people familiar with the matter.

fool.com
Current CVS Health CEO David Joyner took over a little over a year ago. The company's growth rate has been improving and its overall financial results have been stronger.

fool.com
CVS Health has improved its financial results this year. The company's efforts could allow it to maintain that momentum.
See all news